Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 42 min 40 sec ago

Pfizer to Acquire Medivation

Mon, 08/22/2016 - 15:13
NEW YORK & SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Pfizer Inc. (PFE) and Medivation, Inc. (MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical compan...
Biopharmaceuticals, Oncology, Mergers & Acquisitions
Pfizer, Medivation, XTANDI, enzalutamide

Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer

Mon, 08/22/2016 - 14:33
Robert L. Rosiello to Remain at Valeant as Executive Vice President, Corporate Development and Strategy LAVAL, Quebec, Aug. 22, 2016 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today...
Biopharmaceuticals, Dermatology, Personnel
Valeant Pharmaceuticals

Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa(TM) (andexanet alfa), a Factor Xa Inhibitor Antidote

Fri, 08/19/2016 - 15:28
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2016 -- (Healthcare Sales & Marketing Network) -- Portola Pharmaceuticals Inc.® (PTLA) today announced that the MAA for IndexXa™ (andexanet alfa; trade name in the United States is AndexXa™), a Factor Xa inhibitor ...
Biopharmaceuticals, Regulatory
Portola Pharmaceuticals, IndexXa, andexanet alfa, Factor Xa

Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA

Fri, 08/19/2016 - 15:26
LEVERKUSEN, Germany and BASEL, Switzerland, Aug. 19, 2016 -- (Healthcare Sales & Marketing Network) -- Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer ...
Bayer, CRISPR Therapeutics, Casebia Therapeutics

Alere Receives FDA Clearance for Alere(TM) i RSV Rapid Molecular Test

Fri, 08/19/2016 - 15:23
WALTHAM, Mass., Aug. 19, 2016 -- (Healthcare Sales & Marketing Network) -- Alere Inc. (ALR), a global leader in rapid diagnostics, today announced that its Alere™ i RSV test has received 510(k) marketing clearance from the U.S. Food and Drug Administratio...
Diagnostics, FDA
Alere, Respiratory Syncytial Virus, RSV

Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development

Thu, 08/18/2016 - 16:07
LAKE FOREST, Ill., Aug. 18, 2016 -- (Healthcare Sales & Marketing Network) -- Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that Rob Monahan has recently joined Akorn as Senior Vice President of Corporate Developme...
Biopharmaceuticals, Generics, Personnel

Derma Sciences Names Russell Olsen President of Advanced Wound Care

Thu, 08/18/2016 - 16:03
PRINCETON, N.J.--(Healthcare Sales & Marketing Network)--Derma Sciences, Inc. (DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of Russell Olsen as President of Advanced Wound Care. Mr. Olsen is Presid...
Regenerative Medicine, Wound Care, Dermatology, Personnel
Derma Sciences

FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome

Thu, 08/18/2016 - 15:59
PRINCETON, N.J., Aug. 18, 2016 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is ...
Biopharmaceuticals, FDA
Soligenix, dusquetide, macrophage activation syndrome

Avelas Biosciences Completes $20 Million Series C Financing

Thu, 08/18/2016 - 15:56
SAN DIEGO, Aug. 18, 2016 -- (Healthcare Sales & Marketing Network) -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced it has completed a Serie...
Biopharmaceuticals, Oncology, Personnel, Venture Capital
Avelas Biosciences, breast cancer

Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa(TM) (andexanet alfa)

Thu, 08/18/2016 - 15:54
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2016 -- (Healthcare Sales & Marketing Network) -- Portola Pharmaceuticals Inc.® (PTLA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regardin...
Biopharmaceuticals, FDA
Portola Pharmaceuticals, AndexXa, andexanet alfa, Factor Xa

ProclaRx Names Doug Martin as Chief Operating Officer

Wed, 08/17/2016 - 15:19
COLUMBUS, Ohio, Aug. 17, 2016 -- (Healthcare Sales & Marketing Network) -- ProclaRx, a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections, today announced the appointment of Doug Martin as the...
Biopharmaceuticals, Personnel

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

Wed, 08/17/2016 - 14:46
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administrat...
Biopharmaceuticals, Oncology, FDA
Trillium Therapeutics, SIRPaFc, TTI-621, mycosis fungoides

Bovie Medical Receives FDA 510(k) Clearance for Its PlazXact(TM) Ablator

Tue, 08/16/2016 - 15:57
CLEARWATER, Fla.--(Healthcare Sales & Marketing Network)--Bovie Medical Corporation (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that it has received 510(k) clearance fr...
Devices, Orthopaedic, Surgery, FDA
Bovie Medical, PlazXact, arthroscopic

Tioma Therapeutics Announces $86 Million Series A Financing

Tue, 08/16/2016 - 13:20
ST. LOUIS, MO and BRISBANE, CA--(Healthcare Sales & Marketing Network) - Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers, today announced it has raised $...
Biopharmaceuticals, Oncology, Venture Capital
Tioma Therapeutics, CD47

Cardiovascular Systems Names Scott Ward as CEO

Tue, 08/16/2016 - 13:13
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--Cardiovascular Systems, Inc. (CSI) (CSII), today announced that, following a national search, it has named Scott R. Ward, 56, the company’s new Chairman and Chief Executive Officer, effective immedia...
Devices, Cardiology, Personnel
Cardiovascular Systems, Orbital Atherectomy, atherectomy

Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline

Tue, 08/16/2016 - 13:05
SAN DIEGO, Aug. 15, 2016 -- (Healthcare Sales & Marketing Network) -- Scintilla Pharmaceuticals, Inc. ("Scintilla"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has entered into a binding term sheet to acqui...
Biopharmaceuticals, Mergers & Acquisitions
Scintilla Pharmaceuticals, Sorrento Therapeutics, Semnur Pharmaceuticals

Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer

Mon, 08/15/2016 - 15:51
SAN DIEGO, Aug. 15, 2016 -- (Healthcare Sales & Marketing Network) -- Arena Pharmaceuticals, Inc. (ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today. Mr. Aurentz wil...
Biopharmaceuticals, Gastroenterology, Personnel
Arena Pharmaceuticals, etrasimod, ulcerative colitis

Conventus Orthopaedics delivers additional Cage Technology fracture solutions with new Distal Ulna and Proximal Ulna product indications for innovative 3-dimensional fixation

Mon, 08/15/2016 - 13:51
MAPLE GROVE, Minn., Aug. 15, 2016 -- (Healthcare Sales & Marketing Network) -- Conventus Orthopaedics, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new Conventus Cage™ DU (Distal Ulna)...
Devices, Orthopaedic, FDA
Conventus Orthopaedics, Conventus Cage, fracture fixation

Medtronic Completes $20 Million Second Tranche Investment in Mazor Robotics

Mon, 08/15/2016 - 13:45
CAESAREA, Israel--(Healthcare Sales & Marketing Network)--Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced the completion of the second tranche of the equity investment by M...
Devices, Neurosurgery, Venture Capital
Mazor Robotics, Medtronic, Renaissance Guidance System

Siemens and INSIGHTEC Sign Agreement to Expand Access to Exablate Neuro Technology

Mon, 08/15/2016 - 13:36
ERLANGEN, Germany and HAIFA, Israel, Aug. 15, 2016 -- (Healthcare Sales & Marketing Network) -- INSIGHTEC, the global leader in MR-guided Focused Ultrasound (MRgFUS) therapy, announced today the signing of a strategic agreement with the global leader in M...
Devices, Neurology, Radiology
INSIGHTEC, Siemens, MRgFUS, Exablate Neuro, MAGNETOM Aera

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong